Tenax Therapeutics, Inc.
7.23+0.01 (+0.14%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · TENX · USD
Key Stats
Market Cap
32.99MP/E (TTM)
2.46Basic EPS (TTM)
2.94Dividend Yield
0%Recent Filings
8-K
EPO patent grant for TNX-103
Tenax Therapeutics scored a key win as the European Patent Office signaled intent to grant a patent protecting TNX-103 (oral levosimendan) and other formulations for treating PH-HFpEF through at least December 2040. This bolsters IP in Europe, matching North American patient prevalence, while the company gears up for its LEVEL-2 Phase 3 trial recruiting there this year. Patent covers diverse doses and combos with cardiovascular drugs. Yet clinical trials carry inherent risks.
8-K
Expands levosimendan license rights
Tenax Therapeutics expanded its license from Orion Corporation on September 3, 2025, gaining exclusive worldwide rights to develop, commercialize, and manufacture orally-administered levosimendan products, building on existing subcutaneous rights. Orion will supply levosimendan for oral development at low triple-digit thousands in Euros per kilogram. This broadens Tenax's pipeline in critical care. Supply terms ensure GMP compliance.
10-Q
Q2 FY2025 results
Tenax Therapeutics ramped up its Phase 3 LEVEL trial in Q2 FY2025 ended June 30, 2025, driving research and development expenses to $6.1M, up 163% y/y, while general and administrative costs hit $5.7M, up 322% y/y, yielding a net operating loss of $11.8M (221% y/y increase) and net loss of $10.8M after $0.95M interest income. For the six months, operating expenses totaled $23.1M (205% y/y rise), with net loss at $21.3M and diluted EPS of $(0.56) on 38.1M weighted shares, consistent with no anti-dilution effects. Cash burn from operations eased to $13.2M y/y, offset by $23.8M from the March 2025 financing, lifting cash to $105.5M—enough through 2027. Stock-based compensation fueled much of the G&A surge. Yet clinical momentum builds steadily. Regulatory approval remains a key hurdle.
8-K
Q2 loss widens on trial advances
Tenax Therapeutics reported a Q2 2025 net loss of $10.8 million, up from $3.6 million last year, driven by $6.1 million in R&D expenses for its Phase 3 LEVEL study of TNX-103 in PH-HFpEF patients and preparations for the global LEVEL-2 trial. Cash reserves stand at $105.5 million, funding operations through 2027. Enrollment in LEVEL, targeting 230 patients, nears completion in H1 2026, with topline data in H2. Patent allowance in Canada bolsters IP to 2040.
8-K
Annual meeting approves exculpation amendment
Tenax Therapeutics stockholders approved an Officer Exculpation Amendment at the June 11, 2025 annual meeting, shielding certain officers from liability under Delaware law; it became effective June 13, with a restated certificate filed June 16. They elected six directors for one-year terms and ratified Cherry Bekaert as auditors, but rejected a proposal limiting stockholder actions to meetings. Say-on-pay passed, with votes favoring biennial advisory frequency. This bolsters governance protections amid routine annual updates.
ATXS
Astria Therapeutics, Inc.
12.60+0.13
AURX
Nuo Therapeutics, Inc.
2.29+0.00
BIXT
Bioxytran, Inc.
0.06+0.01
BLRX
BioLineRx Ltd.
3.50-0.18
IMA
ImageneBio, Inc.
8.79+0.09
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
MRKR
Marker Therapeutics, Inc.
0.97-0.04
TBPH
Theravance Biopharma, Inc.
14.17+0.07
TNGX
Tango Therapeutics, Inc.
7.83+0.04
TNYA
Tenaya Therapeutics, Inc.
1.43-0.13